Immix Biopharma Inc. has released a presentation highlighting the challenges faced by patients with relapsed or refractory AL amyloidosis in the United States. According to cited sources, approximately 34,000 US patients are affected by this life-threatening condition, which occurs when abnormal antibodies produce toxic light chains that accumulate in organs such as the heart, kidneys, and liver. The presentation outlines the limitations of current treatment options, especially after frontline therapies have failed. It notes that there are no approved drugs for patients with relapsed or refractory AL amyloidosis, and existing second-line therapies yield low complete response rates. The company emphasizes the need for improved therapeutic approaches to address these unmet medical needs. You can access the full presentation through the link below.